Tag: anti-CD20 monoclonal antibody

1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients. 2. Post hoc analysis suggested minimal residual disease negative status and the lack of prior v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors exposure were associated with better survival. Evidence Rating Level: 2...